Armata Pharmaceuticals (ARMP) CEO reports tax withholding of 14,041 shares

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. reported that Chief Executive Officer Deborah Birx had 14,041 shares of common stock withheld on 2026-07-10 at $4.26 per share to satisfy income tax and withholding remittance obligations tied to the net settlement of restricted stock units. After this non-market, tax-withholding disposition, she directly holds 198,417 shares of Armata common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Birx Deborah

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	14,041	$4.26	$60K

Holdings After Transaction: Common Stock — 198,417 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 14,041 shares Withholding price per share: $4.26 per share Shares held after transaction: 198,417 shares

3 metrics

Shares withheld for taxes 14,041 shares Common stock withheld to satisfy income tax and withholding obligations on RSU net settlement

Withholding price per share $4.26 per share Valuation used for the 14,041 withheld shares in the tax-withholding disposition

Shares held after transaction 198,417 shares Directly owned Armata common shares by CEO Deborah Birx after the withholding

Key Terms

restricted stock units, net settlement, withholding remittance obligations

3 terms

restricted stock units financial

"in connection with the net settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

net settlement financial

"to satisfy its income tax obligations in connection with the net settlement"

withholding remittance obligations financial

"to satisfy its income tax and withholding remittance obligations"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/14/2026 - 04:19 PM Accepted by SEC EDGAR 07/14/2026 - 04:18 PM Learn about SEC filing dates

FAQ

What insider transaction did Armata Pharmaceuticals (ARMP) report for Deborah Birx?

Armata Pharmaceuticals reported that CEO Deborah Birx had 14,041 shares of common stock withheld on 2026-07-10. The shares were withheld to cover income tax and withholding obligations related to net settlement of restricted stock units, not an open-market sale.

Was the ARMP CEO’s Form 4 transaction an open-market sale of shares?

No. The transaction for Armata’s CEO involved tax-withholding, not an open-market sale. 14,041 shares were withheld by the company to satisfy income tax and withholding remittance obligations tied to the settlement of restricted stock units.

How many Armata Pharmaceuticals (ARMP) shares does Deborah Birx hold after the reported transaction?

Following the tax-withholding disposition, CEO Deborah Birx directly holds 198,417 shares of Armata Pharmaceuticals common stock. This figure reflects her ownership after 14,041 shares were withheld to cover tax obligations on restricted stock unit settlement.

At what price per share were Deborah Birx’s ARMP shares valued for the tax withholding?

The withheld shares were valued at $4.26 per share for the tax-withholding transaction. In total, 14,041 shares of Armata Pharmaceuticals common stock were withheld to satisfy income tax and withholding remittance obligations tied to restricted stock units.

What was the nature of the restricted stock unit event for Armata Pharmaceuticals (ARMP) CEO?

The event involved a net settlement of restricted stock units, where 14,041 shares were withheld to satisfy income tax and withholding obligations. This is a compensation-related, non-market transaction rather than a discretionary purchase or sale by the CEO.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Birx Deborah

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CALIFORNIA 90066

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		F		14,041(1)	D	$4.26	198,417	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.

	/s/ Deborah Birx	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)